Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Huawei Unveils Financial AI Scaling Capabilities at Singapore FinTech Festival 2026

    November 20, 2026

    Botswana opens consultations on proposed 33 percent hike now

    November 19, 2026

    UnionPay International and Transsion Announce Global Partnership to Bring UnionPay Payments to T Wallet, Debuting in Pakistan

    November 19, 2026
    Facebook X (Twitter) Instagram
    • Home
    • Contact Us
    Sudan HeraldSudan Herald
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • More
      • Sports
      • Technology
      • Travel
    Sudan HeraldSudan Herald
    You are at:Home » Revolutionizing Drug Development: Novigenix Unveils AI-Powered RNA Analysis for Immune Response Profiling
    ACCESS Newswire

    Revolutionizing Drug Development: Novigenix Unveils AI-Powered RNA Analysis for Immune Response Profiling

    January 17, 2024
    Facebook Twitter Pinterest LinkedIn Tumblr Email

    GENEVA, SWITZERLAND / ACCESSWIRE / January 17, 2024 / With cancer projected to escalate to 29 million cases by 2040[1], Novigenix, a pioneer in AI healthcare solutions, is rewriting the rules of cancer care. Their newest innovation, LITOSeek™, is primed to reshape drug development, offering a transformative leap forward.

    From left: Dr. Brian Hashemi, Novigenix’s CEO and Chairman, Dr. Sahar Hosseinian, Co-founder & CTO, and Dr. Pedro Romero, Chief Medical & Scientific Officer

    Personalized Cancer Treatment: Breaking Barriers

    Every cancer is as unique as the person it affects. Tumors are in continuous dynamic interplay with the patient’s immune defenses and are adept at subverting and escaping immune control. Novigenix is on a mission to improve the cancer treatment landscape, leveraging advanced AI and RNA analysis from a routine blood draw to provide more precise insights into patient immune responses to cancer treatments, compared to conventional DNA liquid biopsies that evaluate tumor evolution through circulating tumor DNA (ctDNA). Insights into the precise dynamic of patient immune response thus pave the way for superior therapeutic discoveries in the field.

    Empowering Biopharma: Unveiling LITOSeek™ at Precision Medicine World Conference

    On January 24th at the Precision Medicine World Conference in Silicon Valley, Novigenix will debut LITOSeek™, a groundbreaking solution designed to expedite drug development for biopharma companies.

    AI and RNA Analysis: Pioneering Healthcare Transformation

    With a decade-long track record, Novigenix successfully launched Colox® blood test in Switzerland, powered by AI and RNA analysis to detect early-stage colon cancer, marking a significant departure from invasive colonoscopy procedures. By aggregating data from diverse colon cancer patients, Novigenix identified immune system biomarkers crucial for early-stage detection, enhancing treatment outcomes.

    Dr. Brian Hashemi, Novigenix’s CEO and Chairman, emphasized, “Our experience with Colox® underscores the potential of AI RNA analysis. Ongoing studies across various cancer types have fuelled our Knowledge Base to uncover comprehensive sets of biomarkers via liquid biopsy and AI RNA analysis. Our validated immunotherapy response biomarkers provide early prediction of patient response and we invite biopharma companies to leverage our platform for more efficient and effective drug development.”

    Professor Pedro Romero, M.D. Chief Medical & Scientific Officer of Novigenix, and Founding Chief Editor of the Journal of Immunotherapy of Cancer, highlights the importance of patient immune response in the development of novel therapies: “AI RNA analysis is poised to revolutionize healthcare, accelerating conventional experimental drug development with data-driven precision immune response prediction. By swiftly analyzing systemic immune responses, AI compresses analysis times, expediting traditional drug development and powering discovery of novel therapy targets.”

    A Team Dedicated to the Future of Cancer Care

    With over 20 Ph.D.-level scientists focused on the development of the LITOSeek™ platform and advancing next-generation liquid biopsy solutions, Novigenix is pioneering precision immunology to help transform cancer treatment paradigms for better patient outcomes.

    #Ends#

    [1] https://canceratlas.cancer.org/the-burden/the-burden-of-cancer/

    Contact Information

    Edwin Shankar
    edwin.shankar@leidar.com

    SOURCE: Novigenix

    View the original press release on newswire.com.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    Chevron Signs 3-Year Agreement with UptimeAI, Scaling Expertise to Enhance Asset Reliability and Operational Efficiency

    November 17, 2026

    Miami Fashion Week(R) Celebrates 10 Years With a Landmark Anniversary Edition, October 13-18, 2026

    October 26, 2026

    Payani AI Launches AI-Powered Marketing and Sales Execution: Tell the AI What You Want Done

    October 20, 2026
    Latest News

    Botswana opens consultations on proposed 33 percent hike now

    November 19, 2026

    PM Modi meets Prince and Princess of Wales for climate talks

    November 19, 2026

    Rand slips toward R17 as inflation and weak growth cloud outlook

    November 18, 2026

    Ebola adds 60 cases in a day as Congo deaths hit 5,568

    November 18, 2026

    Dubai Airports expects over 70 million guests in 2026

    November 18, 2026

    Prabowo says DEFA can unlock $2 trillion ASEAN digital economy

    November 18, 2026

    Over 9 million visitors lift Tunisia tourism income 3.4%

    November 17, 2026

    Etihad plans seven weekly Calgary flights as demand grows

    November 17, 2026
    © 2026 Sudan Herald | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.